These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 17989902)

  • 21. Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris.
    Bonomo L; Levitt JO
    Cutis; 2018 May; 101(5):367-369. PubMed ID: 29894526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of juvenile pityriasis rubra pilaris with etanercept.
    Cox V; Lesesky EB; Garcia BD; O'Grady TC
    J Am Acad Dermatol; 2008 Nov; 59(5 Suppl):S113-4. PubMed ID: 19119116
    [No Abstract]   [Full Text] [Related]  

  • 23. Effectiveness of infliximab in pityriasis rubra pilaris is associated with pro-inflammatory cytokine inhibition.
    Adnot-Desanlis L; Antonicelli F; Tabary T; Bernard P; Reguiaï Z
    Dermatology; 2013; 226(1):41-6. PubMed ID: 23548788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxic doses of vitamin A for pityriasis rubra pilaris.
    Randle HW; Diaz-Perez JL; Winkelmann RK
    Arch Dermatol; 1980 Aug; 116(8):888-92. PubMed ID: 7406516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment with infliximab despite positive tuberculosis ELISpot results in a patient with pityriasis rubra pilaris taking prophylactic isoniazid.
    Zirbs M; Kigitsidou E; Seifert F; Ring J; Brockow K
    Clin Exp Dermatol; 2011 Oct; 36(7):808-9. PubMed ID: 21507042
    [No Abstract]   [Full Text] [Related]  

  • 26. Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: A review.
    Maloney NJ; Hisaw LD; Worswick S
    J Am Acad Dermatol; 2018 Sep; 79(3):585-587. PubMed ID: 29518460
    [No Abstract]   [Full Text] [Related]  

  • 27. Erythrodermic pityriasis rubra pilaris: Dramatic response to infliximab therapy.
    Karadag AS; Kavala M; Ozlu E; Ozkanlı S; Zindancı İ; Turkoglu Z
    Indian J Dermatol Venereol Leprol; 2016; 82(1):112. PubMed ID: 26728835
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate.
    Barth D; Harth W; Treudler R; Simon JC
    J Dtsch Dermatol Ges; 2009 Dec; 7(12):1071-4. PubMed ID: 19689446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy.
    Zhang YH; Zhou Y; Ball N; Su MW; Xu JH; Zheng ZZ
    J Cutan Med Surg; 2010; 14(4):185-8. PubMed ID: 20642989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pityriasis rubra pilaris.
    White KL
    Dermatol Online J; 2003 Oct; 9(4):6. PubMed ID: 14594579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stanozolol in the treatment of pityriasis rubra pilaris.
    Pavlidakey GP; Hashimoto K; Savoy LB; Heller GL; Iacobelli D; Barfield L
    Arch Dermatol; 1985 Apr; 121(4):546-8. PubMed ID: 3977380
    [No Abstract]   [Full Text] [Related]  

  • 32. Circumscribed pityriasis rubra pilaris type IV.
    Caldarola G; Zampetti A; De Simone C; Massi G; Amerio P; Feliciani C
    Clin Exp Dermatol; 2007 Jul; 32(4):471-2. PubMed ID: 17239092
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pityriasis rubra pilaris treated with Ro 10-9359--apropos of 2 cases].
    de Bast C; Van Opdenbosch L; De Coninck A
    Dermatologica; 1982 Nov; 165(5):454-7. PubMed ID: 7169118
    [No Abstract]   [Full Text] [Related]  

  • 34. [Erythrodermic pityriasis rubra pilaris].
    Torres Peris V; Aloy Pantín M; Capella Pérez C; Castells Rodellas A
    Med Cutan Ibero Lat Am; 1981; 9(6):423-8. PubMed ID: 7040856
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical improvement of pityriasis rubra pilaris with combination etanercept and acitretin therapy.
    Davis KF; Wu JJ; Murase JE; Rosenberg FR; Sorenson EP; Meshkinpour A
    Arch Dermatol; 2007 Dec; 143(12):1597-9. PubMed ID: 18087024
    [No Abstract]   [Full Text] [Related]  

  • 36. Pityriasis rubra pilaris and cyclosporine.
    Rosenbach A; Lowe NJ
    Arch Dermatol; 1993 Oct; 129(10):1346-8. PubMed ID: 8215510
    [No Abstract]   [Full Text] [Related]  

  • 37. Oral pityriasis rubra pilaris.
    Martinez Calixto LE; Suresh L; Matsumura E; Aguirre A; Radfar L
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 May; 101(5):604-7. PubMed ID: 16632271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists.
    Petrof G; Almaani N; Archer CB; Griffiths WA; Smith CH
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e131-5. PubMed ID: 22324561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exacerbation of pityriasis rubra pilaris under efalizumab therapy.
    Klein A; Szeimies RM; Landthaler M; Karrer S
    Dermatology; 2007; 215(1):72-5. PubMed ID: 17587845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Experience in using photochemotherapy in Devergie's lichen ruber pilaris].
    Kalamkarian AA; Marzeeva GI; Averbakh EV; Olisova MO
    Vestn Dermatol Venerol; 1984 Feb; (2):4-6. PubMed ID: 6720068
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.